PARTNERING WITH BOEHRINGER INGELHEIM

Oncology

Working together with our collaboration partners, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities in oncology and cancer immunology.

Our Oncology Partnering Focus
We are seeking in-licensing and collaborative opportunities at discovery, pre-clinical and clinical stages, for therapeutic programs in our interest areas.

Cancer cell-directed therapies:
- Growth signaling e.g. RTKs, Wnt, Notch, KRAS, MET, MYC, MEK
- Regulation of apoptosis
- Epigenetic regulation
- Regulation of protein homeostasis.

Immune cell-directed therapies:
- Myeloid cell-targeting therapies and innate immune stimulatory pathways
- Tumor stromal concepts and targets
- Cancer vaccines and oncolytic viruses
- Novel tumor antigens for coupling to our T cell engager (TcE) platforms

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

Working together for better health

For more information please contact our BD&L team:
Dr. Ioannis Sapountzis
ioannis.sapountzis@boehringer-ingelheim.com

Dr. Scott M. DeWire
scott.dewire@boehringer-ingelheim.com

Dr. Emilio Erazo-Fischer
emilio.erazo-fischer@boehringer-ingelheim.com

Dr. Marcio Lasaro
marcio.lasaro@boehringer-ingelheim.com